Good day to all.
Wanted to share with you Dr. Patterson on his own words (from Dr. Yo's interview):
That’s a whole SAEs thing in, and, these adverse effects and serious adverse effects and, you know, the question is are they related to the virus? are they related to just something, you know, ah … unrelated to the viral infection is a preexisting condition, whatever, whatever, whatever, ammm; But I think that's important part of running a trial is, is, really evaluating, you know, what's due to the drug and what is no due to drug and eliminating the ones that, that, have nothing to do with the drug.
And so, yeah I do think, you know, it's a really positive sign that, that there is less SAEs, I mean is kind like, you know, the fact I mention it probably 2 months ago that to my knowledge there wasn’t anybody was receiving Leronlimab for HIV that have COVID. And I don’t think there’s anybody who’s been using Leronlimab that have ever had a clotting episode, so again, going back and supporting, you know, the fact that Leronlimab that RANTES plays its role and is produced by activates platelets and forming cloths …so, again, to me as a pathologist and as a virologist, seen, this is a story, right ?, this is this beautiful opera going on … a, beautiful a story .. and narrative that’s being created that is composed of A: understanding COVID across the disease spectrum; B: treating it with something and understanding how that influences the pathogenesis of the virus and then; and C: seeing patients recover in looking at outcomes, but, again I would add to that tonight: post-outcome surveillance; we must have post-outcome surveillance because these people are suffering.
So, that’s what we are here … and, you know, that’s what we are trying to address even while we are still, you know, awaiting trial results. And giving tests help monitor these patients throughout their disease course. So, ammm, it is a very, very interesting time right now, but very similar in many aspects to what I went previously during the early 90’s.
No comments necessary here